Precision Biosciences: Still Swinging And Finally Drawing Blood
2025-12-04 06:38:04 ET
Back in 2023, I covered Precision BioSciences ( DTIL ) when the company was posting positive updates across their gene-editing programs, yet the market shrugged its shoulders. The company's pipeline had programs that could be legitimate best-in-class, which were going to be supported by a strong cash position that could fund the company into early 2025. At the time, my bull thesis was direct: Precision was an under-the-radar biotech with disproportionate upside potential if their pipeline was able to produce approved therapies. I was simply waiting for a bullish signal from the clinic before really committing to DTIL....
Read the full article on Seeking Alpha
For further details see:
Precision Biosciences: Still Swinging And Finally Drawing Blood
NASDAQ: DTIL
DTIL Trading
7.65% G/L:
$5.275 Last:
249,633 Volume:
$4.72 Open:
